Viewray: Eindhoven's Catharina Hospital Purchases ViewRay's MRIdian LinacDate: Monday, 21 December 2020
CLEVELAND, Dec. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.
Catharina Hospital is the largest hospital in the Eindhoven region and a top clinical training facility. It's focused on providing patients with the best care every day with leading experience in cardiovascular care and oncology. Many regional and national hospitals refer patients to Catharina Hospital for their renowned expertise in these areas.
"We believe adding MRIdian to our extensive portfolio of cancer treatments will improve the quality of care we can provide for our patients. Through the use of MRI-guidance and on-table adaptive capabilities, we can improve the accuracy with which we deliver radiation, deliver higher doses in less treatment sessions, and reach tumors that were otherwise virtually unreachable," said Peter-Paul van der Toorn, leading radiation oncologist at Catharina Hospital.
"MRI-guided radiation therapy is rapidly evolving, and we look forward to collaborating with ViewRay in future technology developments and advance the practice of MRI-guided radiation therapy," said Coen Hurkmans, leading clinical physicist at Catharina Hospital
Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. Together with other technical innovations, this offers advantages for the delivery of safe and effective radiotherapy, including the ability to see the tumor and surrounding tissue during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments, continuous tracking of the tumor during treatment, and automatic pausing of the radiation if the tumor moves outside of the boundary. As a result, the system delivers ablative, high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage.
"We're pleased to welcome Catharina Hospital to our family of centers integrating MRIdian into their radiation oncology program," said Paul Ziegler, Senior Vice President of Sales and Marketing at ViewRay. "They have a proven clinical pedigree in effectively treating historically difficult to treat tumors and we believe MRIdian will be the perfect complement to that expertise."
Currently 40 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 11,000 patients have been treated with MRIdian. For a list of treatment centers, please visit: https://viewray.com/mridian-locator.